Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported a 44% decrease in revenue for the first quarter of 2026, totaling $648,140, compared to the same period last year. The decline, as detailed in the company's unaudited financial statements filed on SEDAR+ and OTCIQ, was primarily attributed to a shift in activities for a large project with a major customer that had been anticipated to continue through the year. This client concentration risk underscores the company's ongoing efforts to broaden its service offerings and generate more consistent recurring revenue.
Gross profit for the quarter fell to $202,231, yielding a gross margin of 31.2%, down from 53.6% in Q1 2025. The margin compression resulted from underutilized capacity, as Innovotech maintained staffing and operational readiness in expectation of the planned customer work. Consequently, the company recorded a net and comprehensive loss of $401,295, contrasting with net income of $63,523 in the prior year. Operating expenses rose year over year, reflecting the integration of Keystone Labs and Innovotech Labs, relocation of the former Keystone operations to a new facility, and investments in a strengthened sales organization.
Despite the quarterly setbacks, Innovotech continues to execute its strategic transformation. The company has bolstered its leadership and commercial teams and completed its OTCQB listing in the U.S., enhancing its visibility among American investors. With a strong liquidity position and a meaningful equity base, Innovotech aims to manage near-term volatility while pursuing long-term growth. CEO Craig Milne emphasized management's commitment to building a more diversified, resilient, and scalable platform. “The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk,” Milne stated.
Innovotech, a life sciences services and technology company, specializes in applied microbiology, analytical chemistry, and regulated laboratory services for medical device, pharmaceutical, and industrial clients. Its proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing. Operating through ISO-certified and GMP-accredited laboratories, the company supports clients across multiple sectors, delivering data aligned with regulatory standards from agencies such as the U.S. Food and Drug Administration and Health Canada.
